Acuitas Therapeutics touted preliminary data that evaluated its messenger RNA vaccine for the Zika virus. The company uses a lipid-nanoparticle delivery system to introduce its mRNA vaccine into cells.
The team’s work, which was published in Nature, showed that a single low-dose immunization with its vaccine triggered an immune response in animals and protected them from infection at 2 weeks, 5 weeks and 5 months post-vaccination.
Messenger RNA carries genetic information to code for specific proteins. Vancouver-based Acuitas introduces synthetic mRNA into a cell using its lipid-nanoparticle carriers to instruct the cell to produce a therapeutic protein.